Post-therapy 18F-fluorodeoxyglucose positron emission tomography for predicting outcome in patients with peripheral T cell lymphoma View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2014-10-23

AUTHORS

Naoto Tomita, Yukako Hattori, Shin Fujisawa, Chizuko Hashimoto, Jun Taguchi, Hirotaka Takasaki, Rika Sakai, Ukihide Tateishi, Yoshiaki Ishigatsubo

ABSTRACT

The International Harmonization Project on Lymphoma recommends 18F-fluorodeoxyglucose (FDG)-positron emission tomography (PET) for the routine assessment of treatment efficacy in patients with FDG-avid lymphomas such as Hodgkin’s and diffuse large B cell lymphomas. The utility of FDG-PET in predicting outcomes in patients with peripheral T cell lymphomas (PTCL) has not been fully elucidated. We retrospectively determined the predictive value of FDG-PET after first-line treatment (post-PET) for outcome in PTCL. Of the 36 patients enrolled, 16 were histologically diagnosed with PTCL not otherwise specified and 20 were diagnosed with angioimmunoblastic T cell lymphoma. All patients received curative-intent anthracycline-containing chemotherapy regimens. Post-PET images were visually evaluated by local nuclear medicine physicians. The median observation period for the surviving patients was 44 months. Positive and negative post-PET results were obtained in 31 % (11/36) and 69 % (25/36) of patients, respectively. The 3-year progression-free survival rates in the positive and negative post-PET result groups were 18 % and 62 %, respectively (P < 0.001). Nine of the 11 patients in the positive post-PET result group experienced progressive disease (PD) (positive predictive value, 82 %), whereas 16 of the 25 patients in the negative post-PET result group did not experience PD (negative predictive value, 64 %). The 3-year overall survival rates in the positive and negative post-PET result groups were 44 % and 84 %, respectively (P = 0.03). Our findings indicate that post-PET is predictive of outcome in patients with PTCL. More... »

PAGES

431-436

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s00277-014-2227-5

DOI

http://dx.doi.org/10.1007/s00277-014-2227-5

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1025047126

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/25338967


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged, 80 and over", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Combined Chemotherapy Protocols", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cyclophosphamide", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Doxorubicin", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Fluorodeoxyglucose F18", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Lymphoma, T-Cell, Peripheral", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Positron-Emission Tomography", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Prednisolone", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Prognosis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Retrospective Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Treatment Outcome", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Vincristine", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Department of Internal Medicine and Clinical Immunology, Yokohama City University Graduate School of Medicine, Yokohama, Japan", 
          "id": "http://www.grid.ac/institutes/grid.268441.d", 
          "name": [
            "Department of Internal Medicine and Clinical Immunology, Yokohama City University Graduate School of Medicine, Yokohama, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Tomita", 
        "givenName": "Naoto", 
        "id": "sg:person.01155656464.01", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01155656464.01"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Medical Oncology, Kanagawa Cancer Center, Yokohama, Japan", 
          "id": "http://www.grid.ac/institutes/grid.414944.8", 
          "name": [
            "Department of Medical Oncology, Kanagawa Cancer Center, Yokohama, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hattori", 
        "givenName": "Yukako", 
        "id": "sg:person.01107773320.39", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01107773320.39"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Hematology, Yokohama City University Medical Center, Yokohama, Japan", 
          "id": "http://www.grid.ac/institutes/grid.413045.7", 
          "name": [
            "Department of Hematology, Yokohama City University Medical Center, Yokohama, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Fujisawa", 
        "givenName": "Shin", 
        "id": "sg:person.01145377314.06", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01145377314.06"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Hematology/Oncology, Yamato Municipal Hospital, Yamato, Japan", 
          "id": "http://www.grid.ac/institutes/grid.460144.3", 
          "name": [
            "Department of Hematology/Oncology, Yamato Municipal Hospital, Yamato, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hashimoto", 
        "givenName": "Chizuko", 
        "id": "sg:person.0663571407.30", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0663571407.30"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Hematology, Shizuoka Red Cross Hospital, Shizuoka, Japan", 
          "id": "http://www.grid.ac/institutes/grid.410790.b", 
          "name": [
            "Department of Hematology, Shizuoka Red Cross Hospital, Shizuoka, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Taguchi", 
        "givenName": "Jun", 
        "id": "sg:person.01354366606.35", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01354366606.35"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Medical Oncology, Kanagawa Cancer Center, Yokohama, Japan", 
          "id": "http://www.grid.ac/institutes/grid.414944.8", 
          "name": [
            "Department of Medical Oncology, Kanagawa Cancer Center, Yokohama, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Takasaki", 
        "givenName": "Hirotaka", 
        "id": "sg:person.0774122402.27", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0774122402.27"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Medical Oncology, Kanagawa Cancer Center, Yokohama, Japan", 
          "id": "http://www.grid.ac/institutes/grid.414944.8", 
          "name": [
            "Department of Medical Oncology, Kanagawa Cancer Center, Yokohama, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Sakai", 
        "givenName": "Rika", 
        "id": "sg:person.01300452360.13", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01300452360.13"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Radiology, Yokohama City University Graduate School of Medicine, Yokohama, Japan", 
          "id": "http://www.grid.ac/institutes/grid.268441.d", 
          "name": [
            "Department of Radiology, Yokohama City University Graduate School of Medicine, Yokohama, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Tateishi", 
        "givenName": "Ukihide", 
        "id": "sg:person.0742073556.08", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0742073556.08"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Internal Medicine and Clinical Immunology, Yokohama City University Graduate School of Medicine, Yokohama, Japan", 
          "id": "http://www.grid.ac/institutes/grid.268441.d", 
          "name": [
            "Department of Internal Medicine and Clinical Immunology, Yokohama City University Graduate School of Medicine, Yokohama, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ishigatsubo", 
        "givenName": "Yoshiaki", 
        "id": "sg:person.01125133646.44", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01125133646.44"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/s11899-011-0098-6", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1023101451", 
          "https://doi.org/10.1007/s11899-011-0098-6"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00277-008-0494-8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1016043431", 
          "https://doi.org/10.1007/s00277-008-0494-8"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1532/ijh97.03147", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1028702381", 
          "https://doi.org/10.1532/ijh97.03147"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2014-10-23", 
    "datePublishedReg": "2014-10-23", 
    "description": "The International Harmonization Project on Lymphoma recommends 18F-fluorodeoxyglucose (FDG)-positron emission tomography (PET) for the routine assessment of treatment efficacy in patients with FDG-avid lymphomas such as Hodgkin\u2019s and diffuse large B cell lymphomas. The utility of FDG-PET in predicting outcomes in patients with peripheral T cell lymphomas (PTCL) has not been fully elucidated. We retrospectively determined the predictive value of FDG-PET after first-line treatment (post-PET) for outcome in PTCL. Of the 36 patients enrolled, 16 were histologically diagnosed with PTCL not otherwise specified and 20 were diagnosed with angioimmunoblastic T cell lymphoma. All patients received curative-intent anthracycline-containing chemotherapy regimens. Post-PET images were visually evaluated by local nuclear medicine physicians. The median observation period for the surviving patients was 44\u00a0months. Positive and negative post-PET results were obtained in 31\u00a0% (11/36) and 69\u00a0% (25/36) of patients, respectively. The 3-year progression-free survival rates in the positive and negative post-PET result groups were 18\u00a0% and 62\u00a0%, respectively (P\u2009<\u20090.001). Nine of the 11 patients in the positive post-PET result group experienced progressive disease (PD) (positive predictive value, 82\u00a0%), whereas 16 of the 25 patients in the negative post-PET result group did not experience PD (negative predictive value, 64\u00a0%). The 3-year overall survival rates in the positive and negative post-PET result groups were 44\u00a0% and 84\u00a0%, respectively (P\u2009=\u20090.03). Our findings indicate that post-PET is predictive of outcome in patients with PTCL.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s00277-014-2227-5", 
    "inLanguage": "en", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1358129", 
        "issn": [
          "0939-5555", 
          "1432-0584"
        ], 
        "name": "Annals of Hematology", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "3", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "94"
      }
    ], 
    "keywords": [
      "FDG-PET", 
      "progressive disease", 
      "cell lymphoma", 
      "result group", 
      "anthracycline-containing chemotherapy regimens", 
      "progression-free survival rates", 
      "survival rate", 
      "emission tomography", 
      "first-line treatment", 
      "International Harmonization Project", 
      "FDG-avid lymphomas", 
      "median observation period", 
      "overall survival rate", 
      "nuclear medicine physicians", 
      "positron emission tomography", 
      "chemotherapy regimens", 
      "medicine physicians", 
      "patients", 
      "treatment efficacy", 
      "routine assessment", 
      "lymphoma", 
      "predictive value", 
      "observation period", 
      "PTCL", 
      "outcomes", 
      "PET images", 
      "tomography", 
      "group", 
      "regimens", 
      "disease", 
      "physicians", 
      "months", 
      "Harmonization Project", 
      "Hodgkin", 
      "efficacy", 
      "treatment", 
      "rate", 
      "PET", 
      "findings", 
      "assessment", 
      "period", 
      "utility", 
      "results", 
      "values", 
      "images", 
      "project", 
      "curative-intent anthracycline-containing chemotherapy regimens", 
      "local nuclear medicine physicians", 
      "negative post-PET results", 
      "post-PET results", 
      "negative post-PET result groups", 
      "post-PET result groups", 
      "positive post-PET result group"
    ], 
    "name": "Post-therapy 18F-fluorodeoxyglucose positron emission tomography for predicting outcome in patients with peripheral T cell lymphoma", 
    "pagination": "431-436", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1025047126"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s00277-014-2227-5"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "25338967"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s00277-014-2227-5", 
      "https://app.dimensions.ai/details/publication/pub.1025047126"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2021-12-01T19:32", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20211201/entities/gbq_results/article/article_649.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s00277-014-2227-5"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s00277-014-2227-5'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s00277-014-2227-5'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s00277-014-2227-5'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s00277-014-2227-5'


 

This table displays all metadata directly associated to this object as RDF triples.

269 TRIPLES      22 PREDICATES      100 URIs      89 LITERALS      25 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s00277-014-2227-5 schema:about N09bb11b47e604b86924505aec4cef180
2 N162a52417fc141a6a4ede43f6999354f
3 N189aefcfc09c4daa9e8a6a1b0f0dc879
4 N20d50cca12064e0a891ab28112986ff2
5 N27c13286f4b44a98a575ec20a48f2a14
6 N3f4221612ec643ccbca6fa825233edd7
7 N54917257af38443db75465ec3e2f4733
8 N675488006df04afca2633f2eb3d84f89
9 N6d47b83ff12c4fd8af71c1536add6ec8
10 N74e35fb098a046c0be49f679be314806
11 N75e2a0391a934bac951db9189e9d042b
12 N954dbc93c0b54cb3a10260e23edaf941
13 N96e740d8d0754e73b8fbcf9e42049df5
14 Nac8a1847637c4bee902bf8623324ec38
15 Nb50227bc419d40e985460314e2b990f6
16 Nca5c34e0310a48c5a182c5b57b50eb52
17 Ncaa03339674249bc8ae716e2c9255dcc
18 Ncc57416f0090444a80e60048a11e044d
19 anzsrc-for:11
20 anzsrc-for:1112
21 schema:author Nf50d5bb339804368b0de61795e0acf89
22 schema:citation sg:pub.10.1007/s00277-008-0494-8
23 sg:pub.10.1007/s11899-011-0098-6
24 sg:pub.10.1532/ijh97.03147
25 schema:datePublished 2014-10-23
26 schema:datePublishedReg 2014-10-23
27 schema:description The International Harmonization Project on Lymphoma recommends 18F-fluorodeoxyglucose (FDG)-positron emission tomography (PET) for the routine assessment of treatment efficacy in patients with FDG-avid lymphomas such as Hodgkin’s and diffuse large B cell lymphomas. The utility of FDG-PET in predicting outcomes in patients with peripheral T cell lymphomas (PTCL) has not been fully elucidated. We retrospectively determined the predictive value of FDG-PET after first-line treatment (post-PET) for outcome in PTCL. Of the 36 patients enrolled, 16 were histologically diagnosed with PTCL not otherwise specified and 20 were diagnosed with angioimmunoblastic T cell lymphoma. All patients received curative-intent anthracycline-containing chemotherapy regimens. Post-PET images were visually evaluated by local nuclear medicine physicians. The median observation period for the surviving patients was 44 months. Positive and negative post-PET results were obtained in 31 % (11/36) and 69 % (25/36) of patients, respectively. The 3-year progression-free survival rates in the positive and negative post-PET result groups were 18 % and 62 %, respectively (P < 0.001). Nine of the 11 patients in the positive post-PET result group experienced progressive disease (PD) (positive predictive value, 82 %), whereas 16 of the 25 patients in the negative post-PET result group did not experience PD (negative predictive value, 64 %). The 3-year overall survival rates in the positive and negative post-PET result groups were 44 % and 84 %, respectively (P = 0.03). Our findings indicate that post-PET is predictive of outcome in patients with PTCL.
28 schema:genre article
29 schema:inLanguage en
30 schema:isAccessibleForFree false
31 schema:isPartOf N4c81458a588048d8b67fe80f8f3dd8d5
32 N86dd90d372d14a1496510360cdd46544
33 sg:journal.1358129
34 schema:keywords FDG-PET
35 FDG-avid lymphomas
36 Harmonization Project
37 Hodgkin
38 International Harmonization Project
39 PET
40 PET images
41 PTCL
42 anthracycline-containing chemotherapy regimens
43 assessment
44 cell lymphoma
45 chemotherapy regimens
46 curative-intent anthracycline-containing chemotherapy regimens
47 disease
48 efficacy
49 emission tomography
50 findings
51 first-line treatment
52 group
53 images
54 local nuclear medicine physicians
55 lymphoma
56 median observation period
57 medicine physicians
58 months
59 negative post-PET result groups
60 negative post-PET results
61 nuclear medicine physicians
62 observation period
63 outcomes
64 overall survival rate
65 patients
66 period
67 physicians
68 positive post-PET result group
69 positron emission tomography
70 post-PET result groups
71 post-PET results
72 predictive value
73 progression-free survival rates
74 progressive disease
75 project
76 rate
77 regimens
78 result group
79 results
80 routine assessment
81 survival rate
82 tomography
83 treatment
84 treatment efficacy
85 utility
86 values
87 schema:name Post-therapy 18F-fluorodeoxyglucose positron emission tomography for predicting outcome in patients with peripheral T cell lymphoma
88 schema:pagination 431-436
89 schema:productId Nb2a9a96db1ee4181962e53e22f42580a
90 Nc43316a1fa0e4203ae7f717b7c40c6b7
91 Ncb73da3b5d844a83a8b18b44479bdf66
92 schema:sameAs https://app.dimensions.ai/details/publication/pub.1025047126
93 https://doi.org/10.1007/s00277-014-2227-5
94 schema:sdDatePublished 2021-12-01T19:32
95 schema:sdLicense https://scigraph.springernature.com/explorer/license/
96 schema:sdPublisher Ndaa116826a7745a9a9557cf1516e5a0a
97 schema:url https://doi.org/10.1007/s00277-014-2227-5
98 sgo:license sg:explorer/license/
99 sgo:sdDataset articles
100 rdf:type schema:ScholarlyArticle
101 N09bb11b47e604b86924505aec4cef180 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
102 schema:name Antineoplastic Combined Chemotherapy Protocols
103 rdf:type schema:DefinedTerm
104 N162a52417fc141a6a4ede43f6999354f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
105 schema:name Middle Aged
106 rdf:type schema:DefinedTerm
107 N1897109a74a14bb8bf98361c580046db rdf:first sg:person.01354366606.35
108 rdf:rest N9dede97370574eeab8ffbcff859c6bf2
109 N189aefcfc09c4daa9e8a6a1b0f0dc879 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
110 schema:name Prognosis
111 rdf:type schema:DefinedTerm
112 N1f67c20756d244c994c86c2ac4c81007 rdf:first sg:person.01145377314.06
113 rdf:rest N2f200032a7a74f60ae4e52134fad56e2
114 N20d50cca12064e0a891ab28112986ff2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
115 schema:name Positron-Emission Tomography
116 rdf:type schema:DefinedTerm
117 N24c76d0bd0bc4ddcb255426dcbedae2b rdf:first sg:person.01107773320.39
118 rdf:rest N1f67c20756d244c994c86c2ac4c81007
119 N27c13286f4b44a98a575ec20a48f2a14 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
120 schema:name Adult
121 rdf:type schema:DefinedTerm
122 N2f200032a7a74f60ae4e52134fad56e2 rdf:first sg:person.0663571407.30
123 rdf:rest N1897109a74a14bb8bf98361c580046db
124 N3f4221612ec643ccbca6fa825233edd7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
125 schema:name Retrospective Studies
126 rdf:type schema:DefinedTerm
127 N4c81458a588048d8b67fe80f8f3dd8d5 schema:issueNumber 3
128 rdf:type schema:PublicationIssue
129 N54917257af38443db75465ec3e2f4733 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
130 schema:name Aged
131 rdf:type schema:DefinedTerm
132 N675488006df04afca2633f2eb3d84f89 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
133 schema:name Cyclophosphamide
134 rdf:type schema:DefinedTerm
135 N6d47b83ff12c4fd8af71c1536add6ec8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
136 schema:name Humans
137 rdf:type schema:DefinedTerm
138 N74e35fb098a046c0be49f679be314806 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
139 schema:name Male
140 rdf:type schema:DefinedTerm
141 N75e2a0391a934bac951db9189e9d042b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
142 schema:name Doxorubicin
143 rdf:type schema:DefinedTerm
144 N816c18abca7b45dfb9514a16cb9970db rdf:first sg:person.0742073556.08
145 rdf:rest Nf3499b9ae1974ce9bf69fff946458c6f
146 N86dd90d372d14a1496510360cdd46544 schema:volumeNumber 94
147 rdf:type schema:PublicationVolume
148 N954dbc93c0b54cb3a10260e23edaf941 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
149 schema:name Fluorodeoxyglucose F18
150 rdf:type schema:DefinedTerm
151 N96e740d8d0754e73b8fbcf9e42049df5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
152 schema:name Lymphoma, T-Cell, Peripheral
153 rdf:type schema:DefinedTerm
154 N9dede97370574eeab8ffbcff859c6bf2 rdf:first sg:person.0774122402.27
155 rdf:rest Nfee99fc1a8524a75b8c45e9e6c002a68
156 Nac8a1847637c4bee902bf8623324ec38 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
157 schema:name Treatment Outcome
158 rdf:type schema:DefinedTerm
159 Nb2a9a96db1ee4181962e53e22f42580a schema:name dimensions_id
160 schema:value pub.1025047126
161 rdf:type schema:PropertyValue
162 Nb50227bc419d40e985460314e2b990f6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
163 schema:name Prednisolone
164 rdf:type schema:DefinedTerm
165 Nc43316a1fa0e4203ae7f717b7c40c6b7 schema:name pubmed_id
166 schema:value 25338967
167 rdf:type schema:PropertyValue
168 Nca5c34e0310a48c5a182c5b57b50eb52 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
169 schema:name Vincristine
170 rdf:type schema:DefinedTerm
171 Ncaa03339674249bc8ae716e2c9255dcc schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
172 schema:name Aged, 80 and over
173 rdf:type schema:DefinedTerm
174 Ncb73da3b5d844a83a8b18b44479bdf66 schema:name doi
175 schema:value 10.1007/s00277-014-2227-5
176 rdf:type schema:PropertyValue
177 Ncc57416f0090444a80e60048a11e044d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
178 schema:name Female
179 rdf:type schema:DefinedTerm
180 Ndaa116826a7745a9a9557cf1516e5a0a schema:name Springer Nature - SN SciGraph project
181 rdf:type schema:Organization
182 Nf3499b9ae1974ce9bf69fff946458c6f rdf:first sg:person.01125133646.44
183 rdf:rest rdf:nil
184 Nf50d5bb339804368b0de61795e0acf89 rdf:first sg:person.01155656464.01
185 rdf:rest N24c76d0bd0bc4ddcb255426dcbedae2b
186 Nfee99fc1a8524a75b8c45e9e6c002a68 rdf:first sg:person.01300452360.13
187 rdf:rest N816c18abca7b45dfb9514a16cb9970db
188 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
189 schema:name Medical and Health Sciences
190 rdf:type schema:DefinedTerm
191 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
192 schema:name Oncology and Carcinogenesis
193 rdf:type schema:DefinedTerm
194 sg:journal.1358129 schema:issn 0939-5555
195 1432-0584
196 schema:name Annals of Hematology
197 schema:publisher Springer Nature
198 rdf:type schema:Periodical
199 sg:person.01107773320.39 schema:affiliation grid-institutes:grid.414944.8
200 schema:familyName Hattori
201 schema:givenName Yukako
202 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01107773320.39
203 rdf:type schema:Person
204 sg:person.01125133646.44 schema:affiliation grid-institutes:grid.268441.d
205 schema:familyName Ishigatsubo
206 schema:givenName Yoshiaki
207 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01125133646.44
208 rdf:type schema:Person
209 sg:person.01145377314.06 schema:affiliation grid-institutes:grid.413045.7
210 schema:familyName Fujisawa
211 schema:givenName Shin
212 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01145377314.06
213 rdf:type schema:Person
214 sg:person.01155656464.01 schema:affiliation grid-institutes:grid.268441.d
215 schema:familyName Tomita
216 schema:givenName Naoto
217 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01155656464.01
218 rdf:type schema:Person
219 sg:person.01300452360.13 schema:affiliation grid-institutes:grid.414944.8
220 schema:familyName Sakai
221 schema:givenName Rika
222 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01300452360.13
223 rdf:type schema:Person
224 sg:person.01354366606.35 schema:affiliation grid-institutes:grid.410790.b
225 schema:familyName Taguchi
226 schema:givenName Jun
227 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01354366606.35
228 rdf:type schema:Person
229 sg:person.0663571407.30 schema:affiliation grid-institutes:grid.460144.3
230 schema:familyName Hashimoto
231 schema:givenName Chizuko
232 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0663571407.30
233 rdf:type schema:Person
234 sg:person.0742073556.08 schema:affiliation grid-institutes:grid.268441.d
235 schema:familyName Tateishi
236 schema:givenName Ukihide
237 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0742073556.08
238 rdf:type schema:Person
239 sg:person.0774122402.27 schema:affiliation grid-institutes:grid.414944.8
240 schema:familyName Takasaki
241 schema:givenName Hirotaka
242 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0774122402.27
243 rdf:type schema:Person
244 sg:pub.10.1007/s00277-008-0494-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1016043431
245 https://doi.org/10.1007/s00277-008-0494-8
246 rdf:type schema:CreativeWork
247 sg:pub.10.1007/s11899-011-0098-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1023101451
248 https://doi.org/10.1007/s11899-011-0098-6
249 rdf:type schema:CreativeWork
250 sg:pub.10.1532/ijh97.03147 schema:sameAs https://app.dimensions.ai/details/publication/pub.1028702381
251 https://doi.org/10.1532/ijh97.03147
252 rdf:type schema:CreativeWork
253 grid-institutes:grid.268441.d schema:alternateName Department of Internal Medicine and Clinical Immunology, Yokohama City University Graduate School of Medicine, Yokohama, Japan
254 Department of Radiology, Yokohama City University Graduate School of Medicine, Yokohama, Japan
255 schema:name Department of Internal Medicine and Clinical Immunology, Yokohama City University Graduate School of Medicine, Yokohama, Japan
256 Department of Radiology, Yokohama City University Graduate School of Medicine, Yokohama, Japan
257 rdf:type schema:Organization
258 grid-institutes:grid.410790.b schema:alternateName Department of Hematology, Shizuoka Red Cross Hospital, Shizuoka, Japan
259 schema:name Department of Hematology, Shizuoka Red Cross Hospital, Shizuoka, Japan
260 rdf:type schema:Organization
261 grid-institutes:grid.413045.7 schema:alternateName Department of Hematology, Yokohama City University Medical Center, Yokohama, Japan
262 schema:name Department of Hematology, Yokohama City University Medical Center, Yokohama, Japan
263 rdf:type schema:Organization
264 grid-institutes:grid.414944.8 schema:alternateName Department of Medical Oncology, Kanagawa Cancer Center, Yokohama, Japan
265 schema:name Department of Medical Oncology, Kanagawa Cancer Center, Yokohama, Japan
266 rdf:type schema:Organization
267 grid-institutes:grid.460144.3 schema:alternateName Department of Hematology/Oncology, Yamato Municipal Hospital, Yamato, Japan
268 schema:name Department of Hematology/Oncology, Yamato Municipal Hospital, Yamato, Japan
269 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...